In a significant win for big pharmaceutical firms, a federal judge has refused to certify a consumer and indirect purchaser antitrust class action against GlaxoSmithKline on the grounds that the plaintiffs cannot prove each class member was affected by the alleged scheme to maintain higher prices.
The plaintiffs allege that GSK set out to delay the market date for a generic version of Wellbutrin SR, the sustained-release form of its popular antidepressant, by using “sham” patent litigation to tie up the generic manufacturers in court and proceedings before the patent board.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]